Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

(1) On 19 September 2016, Boehringer Ingelheim (BI) notified a transaction whereby it intends to acquire Merial, the animal health business of Sanofi within the meaning of Article 3(1)(b) of the EC Merger Regulation by way of purchase of assets and shares.

(2) The Transaction is part of a larger operation consisting of an exchange of Sanofi’s Animal Health business (Merial) and BI’s consumer healthcare business.

(3) BI is a privately owned business headquartered in Ingelheim, Germany. BI is active worldwide in the development, production, distribution and marketing of pharmaceuticals, more particularly i) prescription products, ii) consumer healthcare products, iii) biopharmaceuticals and iv) animal health products.

(4) Sanofi is a publicly listed company, headquartered in Paris, France, whose shares are traded on Euronext and the New York Stock Exchange. It is the ultimate parent company of a global healthcare consolidated group consisting of approximately 400 subsidiaries. Sanofi is active in the research, development, manufacture and sale of pharmaceuticals, human vaccines and animal health products.

(5) Merial is Sanofi’s Animal Health business.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.